enVVeno Medical EPS NVNO
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$25.36
- Latest quarter, Q2 FY26
- −$5.37
- Fiscal year 2025
- −$33.37
enVVeno Medical's earnings per share was −$25.36 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$5.37.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$33.37 | n/a |
| FY2024 | −$44.80 | n/a |
| FY2023 | −$68.95 | n/a |
| FY2022 | n/a | n/a |
| FY2021 | −$63.70 | n/a |
| FY2020 | −$252.00 | n/a |
| FY2019 | −$428.75 | n/a |
| FY2018 | −$1872.50 | n/a |
| FY2017 | −$1181.25 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$5.37 | n/a | −$25.36 | |
| Q1 FY26 | −$5.89 | n/a | −$31.51 | |
| Q4 FY25 | −$6.05 | n/a | −$33.37 | |
| Q3 FY25 | −$8.05 | n/a | −$38.17 | |
| Q2 FY25 | −$11.52 | n/a | −$42.37 | |
| Q1 FY25 | −$7.75 | n/a | −$41.70 | |
| Q4 FY24 | −$10.85 | n/a | −$44.80 | |
| Q3 FY24 | −$12.25 | n/a | −$46.90 | |
| Q2 FY24 | −$10.85 | n/a | −$50.40 | |
| Q1 FY24 | −$10.85 | n/a | −$59.85 | |
| Q4 FY23 | −$12.95 | n/a | −$68.95 | |
| Q3 FY23 | −$15.75 | n/a | −$75.25 |
Against its peers
Companies in Healthcare nearest enVVeno Medical's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NVNOenVVeno Medical | −$25.36 | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| MSGMMotorsport Games | $0.43 | +187% a year |
| ATCHAtlasClear | $0.01 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on enVVeno Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.